In vitro study of HIF-1 activation and VEGF release by bFGF in the T47D breast cancer cell line under normoxic conditions: Involvement of PI-3K/Akt and MEK1/ERK pathways

Journal of Pathology

Volumn 205, Issue 4, 2005, Pages 530-536

  Shi, Yong Hong ^a,b   Wang, Yu Xiang ^a   Bingle, Lynne ^c   Gong, Li Hua ^a   Heng, Wan Jie ^a   Li, Yan ^a   Fang, Wei Gang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b INNER MONGOLIA MEDICAL COLLEGE   (China)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Angiogenesis; bFGF; Breast tumour; Hypoxia inducible factor 1 ; VEGF

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; BASIC FIBROBLAST GROWTH FACTOR; CYCLOHEXIMIDE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SYNAPTOPHYSIN; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DATA ANALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMONES; CYCLOHEXIMIDE; DNA-BINDING PROTEINS; ENZYME INHIBITORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MAP KINASE KINASE 1; MORPHOLINES; NUCLEAR PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 14944380568     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1734     Document Type: Article

References (23)

1. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000; 88 1474- 1480.
2. Grimm C, Wenzel A, Groszer M, et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nature Med 2002; 8: 718-724.
3. Gleadle JM, Ratcliffe PJ. Induction of HIF-1, erythropoietin, VEGF, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. Blood 1997; 89: 503-509.
4. Volm M, Koomagi R. HIF-1 and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res 2000; 20: 1527-1533.
5. Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by HIF-1. Cancer Res 2003; 63: 1138-1143.
6. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of HIF-1 α. Genes Dev 2000; 14: 34-44.
7. Kung AL, Wang S, Klco JM, Kaelin WG, Livingston DM. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nature Med 2000; 6: 1335-1340.
8. Jubb AM, Pham TQ, Hanby AM, et al. Expression of VEGF, HIF-1 α, and carbonic anhydrase IX in human tumors. J Clin Pathol 2004; 57: 504-512.
9. Zhong H, Mabjeesh N, Willard M, et al. Nuclear expression of HIF-1 α protein is heterogeneous in human malignant cells under normoxic conditions. Cancer Lett 2002; 181: 233-238.
10. Zhong H, Chiles K, Feldser D, et al. Modulation of HIF-1 α expression by the EGF/PI-3K/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60: 1541-1545.
11. Sang N, Stiehl DP, Bohensky J, et al. MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 2003; 278: 14 013 -14 019.
12. Stiehl DP, Jelkmann W, Wenger RH, Hellwig-Burgel T. Normoxic induction of the HIF-1 α by insulin and IL-1β involves the PI3-K pathway. FEBS Lett 2002; 512: 157-162.
13. Giavazzi R, Giuliani R, Coltrini D, et al. Modulation of tumor angiogenesis by conditional expression of FGF-2 affects early but not established tumors. Cancer Res 2001; 61: 309-317.
14. Saadeh PB, Mehrara BJ, Steinbrech DS, et al. Mechanisms of FGF-2 modulation of VEGF expression by osteoblastic cells. Endocrinology 2000; 141: 2075-2083.
15. Sako A, Kitayama J, Yamaguchi H, et al. VEGF synthesis by human omental mesothelial cells is augmented by FGF-2: possible role of mesothelial cell on the development of peritoneal metastasis. J Surg Res 2003; 115: 113-120.
16. Levin EG, Sikora L, Ding L, Rao SP, Sriramarao P. Suppression of tumor growth and angiogenesis in vivo by a truncated form of 24-kd FGF-2. Am J Pathol 2004; 164: 1183-1190.
17. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 2002; 62: 1702-1706.
18. Blancher C, Moore JW, Talks KL, et al. Relationship of HIF-1α and HIF-2α expression to VEGF induction and hypoxia survival in human breast cancer cell lines. Cancer Res 2000; 60: 7106-7113.
19. Burke B, Tang N, Corke KP, et al. Expression of HIF-Iα by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J Pathol 2002; 196: 204-212.
20. Mohammadi M, McMahon G, Sun L, et al. Structures of the tyrosine kinase domain of FGF receptor in complex with inhibitors. Science 1997; 276: 955-960.
21. Berger AP, Kofler K, Bektic J, et al. Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 2003; 57: 57-65.
22. Pore N, Liu S, Haas-Kogan DA, O'Rourke DM, Maity A. PTEN mutation and EGF receptor activation regulate VEGF mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. Cancer Res 2003; 63: 236-241.
23. Harris VK, Coticchia CM, Kagan BL, Ahmad S, Wellstein A, Riegel AT. Induction of the angiogenic modulator FGF-binding protein by EGF is mediated through both MEK/ERK and p38 signal transduction pathways. J Biol Chem 2000; 275: 10 802-10 811.